Papilloma Viral Infection Clinical Trial
— HPVOfficial title:
HPV Vaccination (Human Papilloma Virus), or How to Address Male Homosexuality in General Practice in Alsace?
NCT number | NCT05078554 |
Other study ID # | 8048 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 27, 2021 |
Est. completion date | January 27, 2022 |
Verified date | October 2021 |
Source | University Hospital, Strasbourg, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The main objective of this study is to find out whether young MSM (men who have sex with men) believe it is important for their GP to be informed of their sexual orientation, in order to improve their clinical, especially with HPV vaccination. The secondary objective is to analyze the state of knowledge about the HPV vaccine and the value of HPV vaccine in this target population.
Status | Completed |
Enrollment | 15 |
Est. completion date | January 27, 2022 |
Est. primary completion date | January 27, 2022 |
Accepts healthy volunteers | |
Gender | Male |
Age group | 18 Years to 26 Years |
Eligibility | Inclusion criteria: - Age: 18-26 years - Consultation at the HUS Cegidd as part of an STI screening - Subject who expressed no opposition to participating in the study Exclusion criteria: - Refusal of the patient to participate in the study - Subject who had already benefited from HPV vaccination (at least one dose) - Inability to give informed consent - Subject under safeguarde of justice - Subject under guardianship or under curatorship |
Country | Name | City | State |
---|---|---|---|
France | Service du Trait d'Union - Hôpitaux Universitaires de Strasbourg | Strasbourg |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Strasbourg, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Retrospective descriptive study of vaccination against HPV (Human Papilloma Virus) in Alsace? | Files analysed retrospectively from April 27, 2021 to January 27, 2020 will be examined] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03584308 -
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
|
Phase 2 | |
Completed |
NCT04459221 -
Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students
|
Phase 4 | |
Not yet recruiting |
NCT06416150 -
Reducing Urban Cervical Cancer Disparities
|
N/A | |
Completed |
NCT02114385 -
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
|
Phase 3 | |
Recruiting |
NCT05916911 -
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
|
Phase 4 | |
Completed |
NCT01030562 -
Immunogenicity of Off-Schedule Dosing of HPV Vaccine
|